The PEAT Act of 2026 aims to prevent biologics from being classified as biological products based solely on the presence of a clinically inactive.
The Protecting Equal Access to Thyroid Act of 2026, or PEAT Act of 2026, amends the Public Health Service Act to ensure that biologics are not treated as biological products if the sole reason is the presence of a protein that is a clinically inactive component. This change aims to maintain equal access to thyroid treatments by preventing unnecessary regulatory hurdles.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.